NCT05706753View on ClinicalTrials.gov

A Study of Milvexian in Healthy Adult Females

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Healthy Female
Interventions
DRUG

Milvexian

Milvexian will be administered orally.

DRUG

Midazolam

Midazolam will be administered orally.

DRUG

Ethinylestradiol

Ethinylestradiol will be administered orally.

DRUG

Drospirenone

Drospirenone will be administered orally.

Trial Locations (1)

2650

SGS Belgium NV, Edegem

Sponsors
All Listed Sponsors
collaborator

Bristol Myers Squibb Company (BMS)

UNKNOWN

lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY